PMID- 35847956
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220719
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse 
      Malignant Peritoneal Mesothelioma: A Pilot Study.
PG  - 811800
LID - 10.3389/fonc.2022.811800 [doi]
LID - 811800
AB  - OBJECTIVE: To investigate the clinical efficacy and adverse events (AEs) of 
      apatinib salvage treatment for diffuse malignant peritoneal mesothelioma (DMPM) 
      that has failed to respond to the recommended treatments. METHODS: 27 patients 
      with refractory DMPM were treated with apatinib at our center from April 2014 to 
      October 2020, at the initial dose of 250 mg/d. The dose was reduced to 125 mg/d 
      when serious adverse events (SAEs) occurred. 28-day was set as a treatment cycle. 
      The frequency of follow up was once every 28 days. The efficacy evaluation was 
      conducted according to the Response Evaluation Criteria in Solid Tumors (RECIST) 
      1.1 criteria and the serum tumor markers before and after apatinib treatment. The 
      safety assessment was performed with the National Cancer Institute (NCI) Common 
      Terminology Criteria for Adverse Events (CTCAE) version 5.0. The primary 
      endpoints were objective response rate (ORR) and disease control rate (DCR), and 
      the secondary endpoints were AEs. RESULTS: The 27 patients completed a median 
      treatment-cycle of 15.0, ranging from 5.1 to 39.4 cycles. At the median follow-up 
      of 14.3 (4.8-51.8) months, median overall survival (OS) was 59.4 months, median 
      apatinib-treatment-related survival (ATRS) was 14.0 (4.8-36.8) months. Complete 
      response (CR) was observed in 0 case (0.0%), partial response (PR) in 4 cases 
      (14.8%), stable disease (SD) in 12 cases (44.4%), and progression disease (PD) in 
      11 cases (40.7%). The ORR was 14.8%, and DCR was 59.3%. The median serum CA125 
      values before and after apatinib treatment were 32.9 (7.0-4592.4) U/mL and 29.7 
      (6.1-4327.4) U/mL, respectively (P=0.009). The common AEs were hypertension 
      (6/27; 22.2%), hand-foot syndrome (5/27; 18.5%), albuminuria (4/27; 14.8%), 
      anemia (4/27; 14.8%), leukopenia (4/27; 14.8%), rash (2/27; 7.4%), fatigue (2/27; 
      7.4%), oral ulcers (2/27; 7.4%), hoarseness (2/27; 7.4%), nausea/vomiting (2/27; 
      7.4%), diarrhea (2/27; 7.4%), headache (1/27; 3.7%), and fever (1/27; 3.7%). The 
      incidence rate of grade III/IV AEs was 16.2%. CONCLUSIONS: Apatinib is effective 
      in treating refractory DMPM, with promising efficacy and acceptable safety.
CI  - Copyright (c) 2022 Yang, Su, Ma, Wu and Li.
FAU - Yang, Zhi-Ran
AU  - Yang ZR
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Su, Yan-Dong
AU  - Su YD
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Ma, Ru
AU  - Ma R
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Wu, He-Liang
AU  - Wu HL
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking 
      University Ninth School of Clinical Medicine, Beijing, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20220701
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9283831
OTO - NOTNLM
OT  - adverse events
OT  - apatinib
OT  - disease control rate
OT  - malignant peritoneal mesothelioma
OT  - tumor makers
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/01/01
CRDT- 2022/07/18 04:22
PHST- 2021/11/09 00:00 [received]
PHST- 2022/06/09 00:00 [accepted]
PHST- 2022/07/18 04:22 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.811800 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jul 1;12:811800. doi: 10.3389/fonc.2022.811800. eCollection 
      2022.